Objective To investigate the association between genetic polymorphisms of glutathione S - transferase P1(GSTP1)and clini-cal outcomes of mFOLFOX6 chemotherapy in patients with advanced colorectal cancer. Methods Genotypes of GSTP1 were determined by matrix- assisted laser desorption / ionization time - of - flight. χ2 test was used for statistical analysis between genotype and objective response,and Log- ranK test on PFS. Results Among 71 enrolled patients,people with GSTP1 rs1695 AA genotype showed both a statistically higher objective re-sponse than those with AG/ GG genotype(60. 8% vs. 30. 0% ,P = 0. 02),and statistically longer PFS[8. 1(95% CI:7. 1 - 9. 1)months vs. 3. 8(95% CI:0. 3 - 7. 3)months,P = 0. 001]. Conclusion GSTP1 rs1695 A > G polymorphisms have a predictive and prognostic contribution towards mFOLFOX6 regimen in advanced colorectal cancer,which represents a further step towards personalized therapy.%目的：探讨谷胱甘肽 S -转移酶 P1（GSTP1）基因多态性对晚期结直肠癌患者化疗疗效的预测价值。方法入组晚期结直肠癌病人71例，采用 mFOLFOX6方案化疗，采用基质辅助激光解吸电离飞行时间确定 GSTP1 rs1695基因型，用χ2检验分析基因型对客观有效率的影响，Kaplan - Merier 法进行生存分析，对数秩检验分析不同基因型患者疾病进展时间的差异。结果携带 GSTP1 rs1695 AA 基因型晚期结直肠癌患者化疗客观有效率（完全缓解+部分缓解）显著高于AG/ GG 基因型（60.8% vs.30.0%，P =0.02），Kaplan - Meier 生存分析显示携带 GSTP1 rs1695 AA 基因型患者疾病进展时间显著长于 AG/ AA 基因型[8.1（95% CI：7.1-9.1）months vs.3.8（95% CI：0.3-7.3）months，P =0.001]。结论GSTP1基因型与晚期结直肠患者 mFOLFOX6方案化疗疗效密切相关，了解 GSTP1基因型可为结直肠癌患者的个体化治疗提供参考。
展开▼
